Invasive vulvar cancer in a woman with human immunodeficiency virus: Case report and review of the literature

Elit, Laurie; Voruganti, S.; Šimunović, Marko

doi:10.1016/j.ygyno.2005.03.039

Cited by 13 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2][3][4][5] In many parts of Africa, ICC is a leading cause of cancer death in women. [2][3][4][5][6][7] Though rates of ICC vary considerably in different sub-regions, cervical cancer ranks first or second (after breast cancer) in all individual sub-Saharan African countries. 8 In subSaharan Africa, over 70,000 new cases occur annually with an age standardized incidence rate of 31.0 per 100,000 women.…”

mentioning

confidence: 99%

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Mugo

Ansah

Marino

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

mentioning

confidence: 99%

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Mugo

Ansah

Marino

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…There are no published prospective trials; however, one retrospective review and several case studies of uterine, vulvar, and vaginal cancers in people living with HIV suggested that patients may present at younger age, respond less to treatment, and have a more aggressive course. One case report of vulvar carcinoma found complete response in a patient treated with definitive chemoradiotherapy 39–42…”

Section: Uterine Ovarian and Vulvovaginal Malignancies In People Livi...mentioning

confidence: 99%

“…One case report of vulvar carcinoma found complete response in a patient treated with definitive chemoradiotherapy. [39][40][41][42] A retrospective review by Levinson et al evaluated 57 patients with gynecological malignancies and HIV (15 vulvar, 26 cervical, nine ovarian, and seven endometrial) treated in the USA. Seventythree percent of patients with stage I disease received NCCNconcordant care compared with only 22% of patients with stage II-IV disease.…”

Section: Cancer Outcomesmentioning

confidence: 99%

Gynecological radiotherapy in people living with human immunodeficiency virus: a semi-systematic literature review

Fenlon

Rositch

Dickey

et al. 2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

Appropriate diagnosis and treatment of gynecological cancers in people living with human immunodeficiency virus (HIV) remains a clinical challenge given rapid changes in both HIV and cancer management and a lack of prospective clinical trial data inclusive of the HIV population. A semi-systematic literature review was performed to identify published studies addressing risk factors, screening, treatment efficacy, treatment toxicity, and prognosis for people living with HIV diagnosed with gynecological malignancies, with a focus on radiotherapy and cervical cancer, given the relative paucity of literature on uterine, ovarian, and vulvovaginal cancers in people living with HIV. People living with HIV are more likely to be co-infected with human papilloma virus and more likely to develop human papilloma virus-associated malignancies. People living with HIV are less likely to receive cancer treatment compared with HIV-uninfected cancer patients, even after adjusting for differences in clinical features and sociodemographic variables. The literature on cervical cancer outcomes is mixed, with some studies demonstrating that people living with HIV have inferior treatment tolerability, response rates, and survival following chemoradiotherapy, and others showing no difference in these outcomes, particularly in patients receiving antiretroviral therapy. Importantly, even in the series showing inferior outcomes in people living with HIV, there were long-term survivors after administration of curative therapy. Consistent with published cancer management guidelines, people living with HIV diagnosed with gynecological cancers should be treated with standard cancer therapy. Co-management with the patient’s HIV specialist is critical to avoid overlapping toxicities and provide optimal supportive care. The morbidity and mortality caused by gynecologic cancers in this population can be mitigated by early diagnosis, appropriate treatment delivery including inclusion of people with HIV in cancer clinical trials, and diligent HIV management.

show abstract

“…Vulval cancer represents ∼3–5% of all gynaecological malignancies and 1% of all female cancers ( Hacker, 2005 ). It is more often seen in older women, although risk factors such as HPV ( Macnab et al , 1986 ) and HIV ( Elit et al , 2005 ) mean that it is also seen in younger women. In 90% of cases, it develops as a squamous cell carcinoma with the remainder being melanoma, Bartholin's gland tumours, adenocarcinoma and basal cell carcinomas.…”

mentioning

confidence: 99%

Cost-effectiveness of sentinel lymph node biopsy vs inguinofemoral lymphadenectomy in women with vulval cancer

et al. 2013

View full text Add to dashboard Cite

Background:This study examines the cost-effectiveness of sentinel lymph node biopsy, a potentially less morbid procedure, compared with inguinofemoral lymphadenectomy (IFL) among women with stage I and stage II vulval squamous cell carcinoma.Methods:A model-based economic evaluation was undertaken based on clinical evidence from a systematic review of published sources. A decision tree model was developed with the structure being informed by clinical input, taking the perspective of the health-care provider.Results:For overall survival for 2 years, IFL was found to be the most cost-effective option and dominated all other strategies, being the least costly and most effective. For morbidity-free related outcomes for 2 years, sentinel lymph node (SLN) biopsy with 99mTc and blue dye and haematoxylin & eosin (H&E) histopathology, with ultrastaging and immunohistochemistry reserved for those that test negative following H&E is likely to be the most effective approach.Conclusion:SLN biopsy using 99mTc and blue dye with ultrastaging may be considered the most cost-effective strategy based on the outcome of survival free of morbidity for 2 years. The findings here also indicate that using blue dye and H&E for the identification of the SLN and the identification of metastasis, respectively, are not sensitive enough to be used on their own.

show abstract

Invasive vulvar cancer in a woman with human immunodeficiency virus: Case report and review of the literature

Cited by 13 publications

References 11 publications

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Gynecological radiotherapy in people living with human immunodeficiency virus: a semi-systematic literature review

Cost-effectiveness of sentinel lymph node biopsy vs inguinofemoral lymphadenectomy in women with vulval cancer

Contact Info

Product

Resources

About